Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder

Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder

US Patent 6517864 · Granted Feb 11, 2003

Estimated economic value: $133,422,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Microrna-based method for assessing the prognosis of a prostate cancer patient2019
Transdermally administered tolterodine as anti-muscarinic agent for the treatmen2006
Transdermally administered tolterodine as anti-muscarinic agent for the treatmen2006
Transdermally administered tolterodine as anti-muscarinic agent for the treatmen2006
Therapeutic formulation for administering tolterodine with controlled release2004
Therapeutic formulation for administering tolterodine with controlled release2004
Therapeutic formulation for administering tolterodine with controlled release2004
Therapeutic formulation for administering tolterodine with controlled release2004
Transdermally administered acetylcysteine as mucolytic agent2003
Transdermally administered acetylcysteine as mucolytic agent2003
Transdermally administered dextromethorphan as antitussive agent2002
Transdermally administered dextromethorphan as antitussive agent2002